natgillin/translations-raw huggingface dataset:
The substance may comprise a liquid, such as mercury, or a powder. 
Podvodno vozilo prema zahtjevu 4, pri čemu je tvar prah.
Apparatus according to anyone of the preceding claims, wherein the resin supplying device is configured for supplying liquid synthetic resin comprising at least one active agent at a first concentration, the active agent being one of: a crosslinking catalyst, a crosslinking accelerator, 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je uređaj za dostavu smole (18) konfiguriran za dostavu tekuće sintetske smole koja sadrži najmanje jedno aktivno sredstvo u prvoj koncentraciji, gdje je aktivno sredstvo jedno od:
In WO 03/104314 A1 there is described a process for processing polyester wastes, for example waste-PET. 
U WO 03/104314 A1 opisan je postupak za obradu poliesterskog otpada, na primjer otpadnog PET.
The preserving reagent in some embodiments comprises a buffer which is selected from the group consisting of BIS-TRIS, BIS-TRIS Propane, HEPES, HEPES Sodium Salt, MES, MES Sodium salt, MOPS, MOPS Sodium Salt, Sodium salt or Sodium Phosphate Buffer (monobasic, tribasic PO4). 
Postupak prema zahtjevu 10, naznačen time da pufer je odabran iz skupine koja sadrži monobazični kalijev fosfat i trobazični kalijev fosfat, BIS-TRIS, BIS-TRIS Propan, HEPES, HEPES natrijevu sol, MES, MES natrijevu sol, MOPS, MOPS natrijevu sol, natrijevu sol, te natrijev fosfatni pufer.
For preparing the solution or suspension of the RIS any appropriate solvent may be used. 
Kemijski sustav prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da RIS jest otopina ili suspenzija u odgovarajućem otapalu.
The compound for use of claim 1, wherein the disease or disorder is multiple myeloma. The compound for use of claim 1, wherein the disease or disorder is glioblastoma. The compound for use of claim 1, wherein the disease or disorder is lymphoma. 
Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je karcinom jajnika. Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak debelog crijeva.
An immunogenic composition comprising an Rv1196 related antigen wherein the Rv1196 related antigen comprises (a) a sequence having at least 90% identity to SEQ ID No: 1 or (b) a fragment of SEQ ID No: 1 which is at least 350 amino acids in length, and wherein the conductivity of the composition is 5 mS/cm or lower and wherein the pH of said composition is in the range 7.0 to 9.0. 
Imunogeni pripravak, naznačen time što sadrži antigen srodan M72, naznačen time što antigen srodan M72 sadrži slijed najmanje 90% istovjetan SEQ ID NO: 1, pH navedenog pripravka je u rasponu od 7,5 do 8,5, a koncentracija natrijevog klorida je 50 mM ili niža.
The solid oral extended release pharmaceutical dosage form of claim 1 or 2, wherein the extended release matrix formulation has a cracking force of at least about 120 N, at least about 130 N or at least about 140 N and/or a "penetration depth to crack distance" of at least about 1.2 mm, preferably of at least about 1.4 mm, at least about 1.5 mm or at least about 1.6 mm. 
Postupak prema zahtjevu 6, naznačen time da se oblik davanja podvrgava temperaturi od barem oko 60 °C ili barem oko 62 °C, poželjno barem oko 68 °C, barem oko 70 °C, barem oko 72 °C ili barem oko 75 °C ili od oko 62 °C do oko 85 °C u vremenskom periodu od barem oko 15 minuta, barem oko 30 minuta, barem oko 60 minuta ili barem oko 90 minuta.
In order to implement the methods and kit of the invention any type of well-known immunoassay can be used, such as for example immunoprecipitation assay, ELISA or RIA, immunofluorescence, Western Blot, FACS analysis, immunocytochemistry/immunohistochemistry. 
In vitro postupak prema bilo kojem od zahtjeva 5 do 9, pri čemu je otkrivanje provedeno tehnikom imunoprecipitacije, imunoanalizom, poželjno ELISA ili RIA ili analizom imunofluorescencije, Western Blot, FACS analizom ili tehnikama imunocitokemije / imunohistokemije.
is optionally substituted C4-7cycloalkyl, or optionally substituted mono-unsaturated-C5-7cycloalkenyl, or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc), or a bicyclic group of sub-formula (ee); 
je izborno supstituirani C4-7cikloalkil, ili izborno supstituirani mononezasićeni-C5-7cikloalkenil, ili izborno supstituirana heterociklička skupina s podformulom (aa), (bb) ili (cc), ili biciklička skupina s podformulom (ee);
The amphiphilic pressure sensitive adhesive composition according to claim 1, wherein the medical device is an ostomy appliance, wound dressing, surgical device, catheter, intravenous delivery device, or infusion device. 
Amfifilna adhezivna smjesa osjetljiva na tlak u skladu s patentnim zahtjevom 1, naznačena time što je medicinska naprava naprava za stomizaciju, zavoj za ranu, kirurška naprava, kateter, naprava za intravenski unos ili naprava za infuziju.
The compound of claim 19 wherein G3 is H and G4 is H. 
Spoj iz zahtjeva 19 gdje je G3 H i G4 je H.
The composition or use of any one of claims 2 or 3, wherein said composition comprises at least one of the following combinations of compounds: 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 3, naznačen time što sadrži najmanje jednu od sljedećih kombinacija lijekova:
The composite material according to claim 1, wherein the composite material is a dental filling material. 
Kompozitni materijal prema bilo kojem prethodnom patentnom zahtjevu, naznačen time da jest materijal za dentalno punilo.
In Figure 8, and also Figure 7, the ring-like second member 18 with the plunger 19 is illustrated wherein it is arranged between the upper surface of upper flange 23 of receiving member 20 and the lower end of outward curl 34, see again Figure 6 . 
Na slici 8, a također 1 na slici 7, prikazan je drugi element 18, koji ima oblik prstena, s klipom 19, pri čemu je taj element postavljen između gornje površine gornje prirubnice 23 elementa za prihvaćanje 20 i donjeg kraja zavijutka 34 koji je okrenut prema vanjskoj strani, vidi također 1 sliku 6.
A population of mammalian stromal stem cells, wherein 30% or more of the cells are positive for Syndecan-2. A population of cell according to claim 1, wherein the cells are mouse, rat, equine or human cells. 
Populacija stromalnih matičnih stanica sisavca, naznačena time da je 30% ili više stanica pozitivno na Syndecan- Populacija stanica prema zahtjevu 1, naznačeno time da su stanice mišje, štakorske, konjske ili humane stanice.
mixing Paliperidone and at least one polymer capable of delaying the release of Paliperidone and capable of swelling upon hydration; and 
miješanje paliperidona i barem jednog polimera koji odgađa oslobađanje paliperidona i koji može nabubriti kada se navlaži; i
Muteins of IL-18BP polypeptides or muteins of viral IL-18BPs, which can be used in accordance with the present invention, or nucleic acid coding therefor, include a finite set of substantially corresponding sequences as substitution peptides or polynucleotides which can be routinely obtained by one of ordinary skill in the art, without undue experimentation, based on the teachings and guidance presented herein. 
Muteini polipeptida IL-18BP ili muteini viralnih IL-18BP, koji se mogu pročišćavati sukladno ovoga izuma ili nukleinske kiseline koje ih kodiraju uključuju definiran set odgovarajućih sekvenci koje su supstitucijski peptidi ili polinukleotidi koji se rutinski mogu dobiti tehnikama koje su poznate stručnjacima bez uporabe vrlo složenih postupaka, a koje se zasnivaju na tehnikama i uputama koje su ovdje predstavljene.
combining said aqueous ammonium nitrate solution and at least a part of the purified aqueous urea solution and/or concentrated urea liquid in a urea ammonium nitrate section so as to obtain an aqueous solution of urea ammonium nitrate; subjecting ammonia-containing off-gas resulting from the production of ammonium nitrate (AN off-gas) to condensation under acidic conditions so as to form an acidic condensate, and using at least part of the acidic condensate as an acidic scrubbing liquid in an off-gas treatment section having a gas inlet in fluid communication with a gas outlet of a finishing section of a urea production unit, wherein the finishing section is adapted to solidify urea liquid, and wherein said off-gas treatment section is adapted to subject ammonia-containing off-gas of the finishing section to treatment with an acidic scrubbing liquid. 
Metoda za modificiranje postrojenja, naznačena time što postrojenje sadrži odjeljak amonijevog nitrata za reakciju amonijaka i dušične kiseline u uvjetima stvaranja amonijevog nitrata, odsječak kondenzacije u fluidnoj komunikaciji s navedenim odjeljkom amonijevog nitrata za kondenzaciju u kiselim uvjetima, otpadni plin iz navedenog dijela amonijevog nitrata, završni dio prilagođen za očvršćivanje tekuće uree i završni odjeljak za obradu koji ima ulaz plina u fluidnoj komunikaciji s izlazom plina navedenog dijela za doradu, prilagođen otpadnim plinovima završne obrade koji sadrže amonijak odjeljak za tretiranje kiselom tekućinom za pročišćavanje, pri čemu metoda uključuje dodavanje veze za komunikaciju tekućine između otvora za kiseli kondenzat navedenog kondenzacijskog dijela i ulaza navedenog dijela za završnu obradu, poput cijevi ili kanala
The compound of claim 4 or 6 wherein R3 and R4 are, independently, H, halogen, methyl, methoxy, or trifluoromethyl. 
Spoj u skladu s patentnim zahtjevom 4 ili 6, naznačen time, da su R3 i R4 neovisno, H, halogen, metil, metoksi ili trifluorometil.
Transformed microalgae according to claim 1 to 5, wherein the glycosylated polypeptide is selected from the group comprising a polypeptide having a primary amino acid sequence of a human glycosylated polypeptide, a primary amino acid sequence of a non-human glycosylated polypeptide, a primary amino acid sequence of an antibody or an active fragment thereof, and/or a primary amino acid sequence of a non-mammalian glycosylated polypeptide. 
Metoda u skladu sa patentnim zahtjevom 1, gdje glikozilirani polipeptid je odabran iz grupe koja sadrži polipeptid koji ima primarnu aminokiselinsku sekvencu humanog glikoziliranog polipeptida, primarnu aminokiselinsku sekvencu ne-humanog glikoziliranog polipeptida, primarnu aminokiselinsku sekvencu antitijela ili njegovog aktivnog dijela, i/ili primarnu aminokiselinsku sekvencu glikoziliranog polipeptida koji nije porijeklom iz sisavaca.
a non-nitrogen based compound having a formula selected from the group consisting of: wherein each R1, R2, R3, and R4 are the same or different and are selected from the group consisting of hydrogen, an alkyl, an alkenyl, an aryl, an acyl, a halogen, a hydroxyl, an alkyl ester, an aryl ester, an alkyl ether, an aryl ether, a hydroxymethyl, an anhydride, and a sulfide; 
[image] [image], gdje je svaki od R1, R2, R3 i R4 isti ili različit i bira se iz skupine koju čine vodik, alkil, alkenil, aril, acil, halogen, hidroksil, alkilni ester, arilni ester, alkil-eter, aril-eter, hidroksimetil, anhidrid, te sulfid;
It is of course also possible that the corresponding pressing element is a part of the external second member or that pressing elements are provided by both members. 
Naravno da je također moguće da su odgovarajući tlačni elementi dio drugog vanjskog elementa ili da su ovi tlačni elementi predviđeni na oba elementa.
The device according to claim 1 wherein there is a mutual connecting zone between the said upright element and base that enables the elastic bending. 
Sustav prema zahtjevu 1, naznačen time da postoji međusobna spojna zona (8) između navedenog uspravnog elementa (5) i baze (6) koja omogućuje elastično savijanje.
receiving, by the target eNB, X2-interface data packets from a source eNB through an X2 interface, which connects the target eNB and the source eNB; receiving, by the target eNB, a special data packet with an end marker from the source eNB through the X2 interface, wherein the special data packet received from the source eNB does not contain user data; and 
regeneriranje (3031), od izvornog eNB, specijalnog paketa podataka sa završnom oznakom u skladu sa posebnim paketom podataka poslanim od SGW, pri čemu regenerirani posebni paket podataka ne sadrži korisničke podatke i nosi broj PDCP sekvence slijedećeg paketa korisničkih podataka koji se treba poslati od izvornog eNB;
If a solid carrier is used for oral administration, the preparation may be tablette, e.g. placed in a hard gelatine capsule in powder or pellet form or e.g. in the form of a troche or lozenge. 
Ukoliko se za oralno davanje koristi kruti nosač, pripravak može biti tableta stavljena u, npr. kapsulu iz. tvrde želatine, u obliku praška ili peleta ili, npr. u obliku pilule ili pastile.
X represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; 
R4 gdje: X predstavlja dva atoma vodika, atom sumpora, atom kisika ili C,.» alkilnu skupinu i atom vodika;
the composition comprises sodium ions, potassium ions, phosphate ions, chloride ions, polysorbate-80, and dextran; 
(ix) farmaceutski sastav obuhvaća natrijeve ione, kalijeve ione, fosfatne ione, kloridne ione, polisorbat-80 1 dekstran;
a coffee cup section (14) where the cup with which the cooked coffee will be served is placed, 
- - postolje za šalicu (14) na koje se postavlja šalica u kojoj će se poslužiti skuhana kava,
The known methods for isolating a statin from a fermentation broth, however, are ill-suited for isolating pure pravastatin, in particular from the pravastatin sodium salt. 
Poznate metode izolacije statina iz fermentacijskog bujona ipak nisu prikladne za izolaciju čistog pravastatina, posebno iz natrijeve soli pravastatina.
Auditory hallucinations, particularly the experience of hearing voices, are a common and often prominent feature of psychosis. 
Slušne halucinacije, posebno doživljaj slušanja glasova, su opći 1 često istaknuti oblik psihoze.
A method for the quantification of a vaccine strain and a virulent strain of Marek's Disease Virus Serotype-1 (MDV-1) in a sample from a bird, comprising the steps of: 
Postupak kvantificiranja cjepivnog soja i virulentnog soja virusa Marekove bolesti serotip-1 (MDYV-1) u uzorku iz ptice, naznačen time što se sastoji u koracima:
identifying the peptide of which CTL inducibility is same to or higher than a peptide consisting of the original amino acid sequence. 
(v) identificiranja peptida čija je CTL inducibilnost ista kao ili veća nego za peptid koji se sastoji od izvornog aminokiselinskog slijeda,
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahijevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluoromelil-1-melil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, a kao komponentu (B) biksafen.
In some embodiments, the N-linked oligosaccharide chain comprises at least one branch having the structure NeuNAc2a3GalB4GlcNAcB2Mana6. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, da oligosaharidni lanac sadržava najmanje jednu granu koja ima strukturu NeuNAc20a3Galp4GlcNAcB2Mana6.
The method of any previous claim wherein the probes may contain within a longer sequence or comprise solely of the following sequences or a fragment thereof: Vaccine strain-specific probe: 5' CCCACCGTGACAGCC 3' 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što sonde mogu u sebi sadržavati dulji slijed ili se sastojati samo od sljedećih sljedova ili njihovih fragmenata:
Calculate the % solids as follows: EPMATHMARKEREP where 
Izračuna se % čvrste tvari kako slijedi:
nozzle 77 (FIG. 3 f) is then moved into position close to the larger components (e.g. transformers, inductors, connectors) on printed circuit 38, and resin 40 is poured so as to expel any air beneath and/or inside the components; 
- - mlaznica 77 (Slika 3f) se premješta u položaj bliži većim komponentama (na pr. transformatorima, induktorima, konektorima) na štampanom krugu 38 i smola 40 se nalijeva tako da istjera sav zrak ispod iili unutar kompononenata;
A still further aspect of the present invention provides Compound 1, a substantially pure diastereomer thereof, or a pharmaceutically acceptable salt thereof, or Compound 2, a substantially pure diastereomer thereof, or a pharmaceutically acceptable salt thereof, for use in the treatment of lung cancer. 
Spoj u skladu s patentnim zahtjevom 1 ili 2, ili njegov dijastereomer, u skladu s patentnim zahtjevima 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 5 u liječenju raka pluća.
Ulipristal acetate (17a-acetoxy-11B-[4- N, N -dimethylamino-phenyl)-19-norpregna-4, 9-diene-3, 20-dione), or any metabolite thereof, for use in treating or preventing a tumour derived from leiomyomata in a patient. 
Ulipristal acetat (17a-acetoksi-118-[4-N,N-dimetilamino-fenil)-19-norpregna-4,9-dien-3,20-dion) ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida.
The assembly of claim 6, wherein the actuators (219, 220) are electrical actuators or hydraulic actuators. 
Montažni sklop prema zahtjevu 6, naznačen time, da se kod aktivatora (219, 220) radi o električnim ili hidrauličnim napravama za stavljanje u pogon drugog mehanizma.
A method for preparing cycloalkenyl aryl derivatives of formula 1, the method comprising the steps of: subjecting compound of the following formula 3 and a compound of the following formula 6 to the reduction to prepare a compound of the following formula 8, and then subjecting the obtained compound of the formula 8 to formation of a ring; and 
podvrgnuti spoj formule 3 i spoj formule 6 redukciji radi pripreme spoja formule 8, i onda dobiveni spoj formule 8 oblikovati u prsten; i podvrgnuti dobiveni spoj formule 9 Suzuki reakciji sa spojem formule 4 uz prisutnost paladijuma radi pripreme spoja formule 1:
The compound according to [5] or a pharmacologically acceptable salt thereof, wherein in the formula (I), Ar2 is a group selected from the group consisting of A1), A2a), A3), and A7a): 
Spoj u skladu sa patentnim zahtjevom 5 ili njegova farmakološki prihvatljiva sol, ili njegov solvat ili hidrat, gdje u formuli (I), Ar? je grupa odabrana iz grupe koja se sastoji od A1), A2), A3), i A7a):
D-methadone for use according to claim 1, wherein the subject has a central nervous system, and wherein the NMDA receptor is located in the central nervous system. 
D-metadon za uporabu prema zahtjevu 1, naznačen time što subjekt ima središnji živčani sustav, i pri čemu je NMDA receptor smješten u središnjem živčanom sustavu.
letting the vacuum in the evaporation chambers to be self-maintained during the desalinating operation. 
– puštanja da se vakuum u otparivačkim komorama održava sam tijekom radnje odsoljavanja.
The method of claim 1, the prodrug compound is represented by a structure of Formula 3 or stereoisomer thereof or pharmaceutically acceptable salt thereof 
t ž u pg Sunnala Fuemalt 2 1, tvar sadrži strukturu Formule 3 ili njen stereoizomer ili njenu farmaceutski
The method of claim 8, wherein the subject is at risk of transient cerebral ischemic attack or stroke as a result of undergoing heart surgery. 
Farmakološko sredstvo za uporabu prema zahtjevu 9, naznačeno time da uporaba je profilaksa subjekta koji je u opasnosti od prolaznog cerebralnog ishemijskog udara ili kapi kao rezultata podvrgavanja operaciji srca.
R1a and R2a taken together with the nitrogen atom to which they are attached form a 3- to 8-membered optionally substituted heterocyclo; 
R'*i R* uzeti zajedno s atomom dušika za koji su pričvršćeni tvore 3- do 8- člani opcionalno supstituirani heterocikil;
contacting said biological sample with a DNA primer pair comprising DNA molecules of sufficient length of contiguous nucleotides of SEQ ID NO:3 or the complement thereof, SEQ ID NO:4 or the complement thereof, SEQ ID NO:5 or the complement thereof, to function as DNA primers or probes specific for DNA extracted from corn plant MON89034 or progeny thereof, wherein said DNA primer pair when used together in a DNA amplification method produces an amplicon comprising SEQ ID NO:1, SEQ ID NO:2, or the complement thereof; 
(a) miješanje spomenutog biološkog uzorka sa parom DNA začetnica koje sadrže DNA molekule od najmanje 18 u nizu poredanih nukleotida SEQ ID NO: 3 ili njenih komplementarnih sekvenci, SEQ ID NO: 4, ili njenih komplementarnih sekvenci, SEQ ID NO: 5 ili njenih komplementarnih sekvenci, da funkcioniraju kao DNA začetnice ili dijagnostičke probe za DNA izdvojenu iz biljke kukuruza oznake MON89034 ili njenih potomaka;
a step of producing the compound of the formula (8) from the compound of the formula (9): (in the formula, Ts represents p-toluenesulfonyl, Ph represents phenyl, and R1 represents a linear or branched C1-6 alkyl); or 
[image] (u formuli Ts predstavlja p-toluensulfonil, Ph predstavlja fenil, a R1 predstavlja nerazgranati ili razgranati C1-6alkil); ili (X-2) postupkom dobivanja spoja formule (8) prikazanim u reakcijskoj shemi niže, koji se sastoji u:
Then the organic partition was washed with brine and then dried over sodium sulfate before evaporating to a solid of Formula 10 (or Formula 11). 
Tada je organski dio bio ispran slanom vodom i tada osušen iznad natrij sulfata prije uparavanja u krutu tvar formule 10 (ili formule 11).
Process according to any one of Claims 1 to 6, in which step b) comprises: a first separation step S1 which consists in the separation of the said mixture of products inside a main column C1 into fraction A at the top of column C1, into fraction C at the bottom of column C1 and into fraction F1 drawn off from the side of column C1, and 
Postupak prema bilo kojem od zahtjeva 1 do 6, naznačen time da korak b) obuhvaća: - prvi korak odvajanja SI koji se sastoji u odvajanju navedene mješavine produkata unutar glavne kolone C1 u frakciju A na vrhu kolone CI, u frakciju C na dnu kolone CI i u frakciju F1 koja je izvučena sa strane kolone CI, te
The polypeptide of claim 3 or 4, wherein said human sclerostin is treated with trypsin to achieve complete trypsin digestion and said polypeptide is isolated by HPLC. 
Polipeptid u skladu patentnim zahtjevom 3 ili 4, naznačen time, da se rečeni ljudski sklerostin tretira s tripsinom, kako bi se postigla potpuna digestija tripsina, a rečeni polipeptid se izolira tekućom kromatografijom visokog učinka (HPLC).
the buprenorphine; wherein the mixing is performed for a sufficient period of time effective to form the flowable composition for use as a controlled release implant, preferably the biodegradable thermoplastic polyester and the biocompatible polar aprotic liquid are mixed together to form a mixture, which is then mixed with the buprenorphine to form the flowable composition. 
buprenorfina; Gdje se miješanje provodi kroz dovoljno vremensko razdoblje djelotvorno za oblikovanje tekućeg pripravka za upotrebu kao implantata s kontroliranim otpuštanjem. Postupak sukladno zahtjevu 14, pri čemu se biorazgradivi termoplastični poliester i biokompatibilna polara aprotonska tekućina međusobno miješaju da bi oblikovali smjesu, koja se zatim miješa s buprenorfinom da bi se oblikovao tekući pripravak.
or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof, wherein the method comprises: 
(I s o ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese; obradi spoja formule (5):